CECAD Microsite

Lung Cancer

Lung cancer is the most common cause of cancer deaths in the Western World. While acceptable disease control can be achieved by surgery and multimodality treatments in non-metastasized stages, systemic chemotherapy for stage IV disease only results in minimal overall survival gains. The development of novel high-throughput DNA sequencing technologies has recently enabled the detection of tumor cell-specific somatic mutations at single-base resolution. Such mutations lead to irreversible alterations in intracellular signal transduction networks to an extent that cancer cells become addicted to the rewired oncogenic signaling. Pharmacological interception of the gene products of these cancer-driving oncogenic mutations has recently produced remarkable therapeutic responses in lung cancer patients. Thus, a detailed understanding these cancer-driving mutations, as well as their impact on cellular signal transduction pathways is a crucial prerequisite to the development of novel therapeutic strategies for fighting cancer.

We have assembled and developed a collection of genetically engineered mouse models mimicking human small cell and non-small cell lung cancer. We use advanced single, dual and triple recombinase strategies to carefully mimic lung cancer initiation, local progression and metastasis. We use these models a preclinical and paraclinical platform to validate therapeutic principles that were conceived on our in vitro functional genomics platform.